Streamex Chairman’s 34,000‑Share Buy Adds 300k‑Plus Position Amid Token Push

Insider Buying Frenzy: Lekstrom Morgan Lee Adds 34,000 Shares to Streamex Corp. Holdings

On May 28, 2026, Interim Executive Chairman Lekstrom Morgan Lee executed a purchase of 34,000 shares of Streamex Corp. at $1.47 per share, adding to an already substantial position that now exceeds 309,000 shares. The transaction comes just days after a flurry of insider activity—most notably a 2026‑05‑21 batch of three large purchases totaling 147,000 shares—and follows a modest price decline of 0.03% to $1.47. Social‑media sentiment is mildly positive (+7) and buzz is slightly below average (10.16 %)—suggesting that the move is largely viewed as a neutral signal rather than a headline‑making event.

What Investors Should Take Away

The consistent buying by the chairman is a classic “confidence cue.” Lee has already accumulated more than 300,000 shares through a series of purchases since February 2026, often at prices ranging from $1.02 to $1.07. While the company’s share price has posted a dramatic 71.7 % monthly rise and a 35.8 % weekly increase, the broader market remains volatile: the stock’s 52‑week low sits at $0.70, and the negative price‑earnings ratio (-13.88) signals that earnings are still a long way from breakeven. Lee’s willingness to continue buying in this environment indicates that the executive believes the company’s recent initiatives—particularly the launch of the GLDY token on a Solana‑based secondary liquidity platform—will unlock new value. For investors, the buying may be a cue to keep an eye on the token’s performance and on any regulatory developments that could accelerate tokenized trading for healthcare equipment and supplies.

Lee’s Insider‑Trading Profile

Lekstrom Morgan Lee’s transaction history paints a portrait of a patient, long‑term investor. In February and March 2026, he executed several sizeable purchases (up to 50,000 shares) at $2.50 and $3.06, respectively, and has since been adding shares in the $1.00–$1.07 range. Notably, he sold 12,759 shares in April 2026 at $1.07, suggesting that he occasionally takes a small profit or rebalances his portfolio. Compared to other executives—such as Chief Investment Officer Williams Mitchell Young, who bought 2.25 million shares in early April—the chairman’s activity is more measured but consistently upward. His pattern of buying at modest discounts to the market price implies a belief that the stock is undervalued relative to its future growth prospects, especially given the company’s innovative GLDY token initiative and its strategic positioning in the high‑growth healthcare equipment sector.

Implications for the Company’s Future

Streamex’s recent move into tokenized assets is a bold step that could reshape liquidity for its gold‑backed GLDY token. If regulatory approvals come through, the platform could become a benchmark for tokenized securities and provide an alternative revenue stream that is less correlated with traditional stock market volatility. Lee’s continued buying supports the narrative that the company is on the cusp of a significant shift—either through increased adoption of its token platform or by leveraging its medical technology expertise to capture market share in the cardiac catheterization space. Investors should monitor both the token’s trading volume and any forthcoming earnings guidance, as the company’s current negative P/E ratio signals that profitability may still be years away. Nevertheless, the chairman’s steady accumulation of shares indicates a strong conviction that the long‑term upside outweighs short‑term price swings.